68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level

Clinical Nuclear Medicine

Volumn 37, Issue 6, 2012, Pages 591-592

  Nicolini, Silvia ^a   Valentina, Ambrosini ^a   Lorenzo, Fantini ^a   Stefano, Fanti ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

68Ga DOTANOC; medullary thyroid carcinoma; PET CT

Indexed keywords

(TETRAXETAN 1 NAL3)OCTREOTIDE GALLIUM GA 68; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA-DOTANOC; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA; BONE TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SCINTISCANNING; THYROID CANCER; THYROID TUMOR;

BONE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; THYROID NEOPLASMS;

EID: 84861437736     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824c5eab     Document Type: Article

References (8)

1. Zatelli MC, Piccin D, Tagliati F, et al. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab. 2006;91:2218-2224. (Pubitemid 43855009)
2. Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641-649. (Pubitemid 34208908)
3. Antunes P, Ginj M, Zhang H, et al. Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993. (Pubitemid 46919547)
4. AmbrosiniV, CampanaD, Bodei L, et al. 68Ga DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
5. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214-1221.
6. Ambrosini V, Nanni C, Zompatori M, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:722-727.
7. Beheshti M, Pocher S, Vali R, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425-1434.
8. Conry BG, Papathanasiou ND, Prakash V, et al. Comparison of (68)Ga- DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49-57.